Most Read Articles
3 months ago
Patients with Sjögren’s syndrome (SS) appear to manifest symptoms such as dysphagia, with swallowing dysfunction substantially reducing the patient quality of life, a study has shown.
Pearl Toh, 6 months ago
Concomitant statin therapy was associated with an attenuation of tocilizumab (TCZ)-mediated increase in serum lipids in patients with rheumatoid arthritis (RA), according to a recent post hoc analysis of randomized clinical studies.
Jairia Dela Cruz, 5 months ago
Patients with early rheumatoid arthritis (RA) may benefit from the initial addition of certolizumab pegol (CZP) to optimized methotrexate (MTX) therapy, as this strategy potentially prevents joint destruction, according to the results of the phase III C-OPERA* study.
Tristan Manalac, 4 months ago
Joint mobilization, ultrasound therapy and therapeutic exercises may improve the range of motion of the ankle and decrease pain in patients with tibia and fibula fractures after cast removal, reports a study presented at the 7th Association of South-East Asian Pain Societies (ASEAPS) Congress 2017.

Adalimumab plus MTX effective in JIA-associated uveitis

2 months ago

Combination therapy with methotrexate (MTX) and adalimumab, a human anti–tumour necrosis factor α monoclonal antibody, is effective in the treatment of juvenile idiopathic arthritis (JIA)-associated uveitis, according to a recent report.


In the multicentre, double-blind study, researchers assessed the efficacy and safety of adalimumab in children and adolescents ≥2 years of age who had active JIA-associated uveitis and who were receiving a stable dose of MTX. The children were randomized in a 2:1 ratio to receive subcutaneous adalimumab (20 or 40 mg based on body weight) or placebo every 2 weeks until treatment failure or until 18 months had elapsed. They were followed-up for 2 years from the time of randomization. The primary endpoint was time to treatment failure.


The trial was halted early when the prespecified stopping criteria were met after the enrolment of 90 of 114 patients. It was clear that the therapy was effective as the treatment failure rate was 27 percent among adalimumab recipients but 60 percent among those in the placebo group (hazard ratio (HR), 0.25, 95 percent confidence interval (CI) 0.12–0.49; p<0.0001 (this HR was the prespecified stopping boundary). However, the rates of adverse events (10.07 events/patient-year vs 6.51 events/patient-year) and serious adverse events (0.29 events/patient-year vs 0.19 events/patient-year) were also higher among adalimumab recipients. 

Editor's Recommendations
Most Read Articles
3 months ago
Patients with Sjögren’s syndrome (SS) appear to manifest symptoms such as dysphagia, with swallowing dysfunction substantially reducing the patient quality of life, a study has shown.
Pearl Toh, 6 months ago
Concomitant statin therapy was associated with an attenuation of tocilizumab (TCZ)-mediated increase in serum lipids in patients with rheumatoid arthritis (RA), according to a recent post hoc analysis of randomized clinical studies.
Jairia Dela Cruz, 5 months ago
Patients with early rheumatoid arthritis (RA) may benefit from the initial addition of certolizumab pegol (CZP) to optimized methotrexate (MTX) therapy, as this strategy potentially prevents joint destruction, according to the results of the phase III C-OPERA* study.
Tristan Manalac, 4 months ago
Joint mobilization, ultrasound therapy and therapeutic exercises may improve the range of motion of the ankle and decrease pain in patients with tibia and fibula fractures after cast removal, reports a study presented at the 7th Association of South-East Asian Pain Societies (ASEAPS) Congress 2017.